Search Results - "Goemans, BF"

Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia by GOEMANS, B. F, ZWAAN, Ch. M, KASPERS, G. J. L, HEINRICH, M. C, MILLER, M, ZIMMERMANN, M, HARLOW, A, MESHINCHI, S, LOONEN, A. H, HIHLEN, K, REINHARDT, D, CREUTZIG, U

“…Activating mutations in RAS and receptor tyrosine kinases such as KIT and FLT3 are hypothesized to cooperate with chimeric transcription factors in the…”
Get full text

In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets by Goemans, Bianca F., Zwaan, Christian M., Harlow, Amy, Loonen, Anne H., Gibson, Brenda E.S., Hählen, Karel, Reinhardt, Dirk, Creutzig, Ursula, Heinrich, Michael C., Kaspers, Gertjan J.L.

“…Although the prognosis of pediatric leukemias has improved considerably, many patients still have relapses. Tipifarnib, a farnesyl transferase inhibitor (FTI),…”
Get full text

Differences in the prevalence of PTPN11 mutations in FAB M5 paediatric acute myeloid leukaemia by Goemans, B. F., Zwaan, Ch. M., Martinelli, S., Harrell, P., Lange, D., Carta, C., Reinhardt, D., Hählen, K., Creutzig, U., Tartaglia, M., Heinrich, M. C., Kaspers, G. J. L.

Get full text

A comparison of the in vitro cytotoxicity of daunorubicin and liposomal daunorubicin in pediatric acute leukemia by Goemans, BF, Zwaan, CM, Reinhardt, D, Gibson, BE, Hahlen, K, Kaspers, GJ

“…Anthracyclines are effective in the treatment of leukemia, but their use is limited because of cardiotoxicity. Liposomal daunorubicin (L-DNR) is potentially…”
Get full text